Drug Profile
Research programme : alpha-1A adrenergic antagonists - SOM Biotech
Alternative Names: Benign prostatic hyperplasia therapeutics - SOM Biotech; SOM2391; SOM2393Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator SOM Biotech
- Class
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Benign prostatic hyperplasia in Spain (unspecified route)
- 28 May 2020 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in Spain
- 12 Apr 2016 Research programme : alpha-1A adrenergic antagonists - SOM Biotech is available for licensing as of 12 Apr 2016. http://www.sombiotech.com